LVW Advisors LLC Has $613,000 Stake in ResMed Inc. (NYSE:RMD)

LVW Advisors LLC lifted its stake in shares of ResMed Inc. (NYSE:RMD) by 84.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,511 shares of the medical equipment provider’s stock after buying an additional 1,150 shares during the quarter. LVW Advisors LLC’s holdings in ResMed were worth $613,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. OFI Invest Asset Management acquired a new stake in shares of ResMed during the 2nd quarter worth approximately $32,000. BOK Financial Private Wealth Inc. acquired a new stake in ResMed in the 1st quarter valued at $35,000. Versant Capital Management Inc grew its position in ResMed by 196.7% in the 2nd quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 120 shares during the period. Financial Connections Group Inc. acquired a new stake in ResMed in the 2nd quarter valued at $37,000. Finally, Riverview Trust Co purchased a new position in ResMed during the 1st quarter worth $42,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In other ResMed news, General Counsel Michael J. Rider sold 882 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total value of $203,742.00. Following the completion of the sale, the general counsel now owns 10,512 shares in the company, valued at approximately $2,428,272. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other ResMed news, General Counsel Michael J. Rider sold 882 shares of ResMed stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total transaction of $203,742.00. Following the sale, the general counsel now directly owns 10,512 shares of the company’s stock, valued at approximately $2,428,272. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael J. Farrell sold 14,683 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $214.25, for a total value of $3,145,832.75. Following the transaction, the chief executive officer now owns 440,799 shares in the company, valued at $94,441,185.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 119,614 shares of company stock worth $27,135,217. 1.21% of the stock is currently owned by insiders.

ResMed Stock Up 1.1 %

Shares of NYSE RMD opened at $240.51 on Friday. ResMed Inc. has a 12 month low of $132.24 and a 12 month high of $255.18. The company has a current ratio of 2.59, a quick ratio of 1.69 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $35.33 billion, a price-to-earnings ratio of 36.94, a PEG ratio of 2.14 and a beta of 0.69. The business has a 50-day moving average of $236.01 and a 200-day moving average of $214.01.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.05. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.22 billion. ResMed had a return on equity of 25.00% and a net margin of 21.79%. ResMed’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.60 earnings per share. Sell-side analysts expect that ResMed Inc. will post 9.02 earnings per share for the current fiscal year.

ResMed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th were given a $0.53 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $2.12 annualized dividend and a yield of 0.88%. This is an increase from ResMed’s previous quarterly dividend of $0.48. ResMed’s payout ratio is presently 32.57%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on RMD shares. KeyCorp lifted their price objective on shares of ResMed from $238.00 to $251.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Robert W. Baird assumed coverage on shares of ResMed in a report on Tuesday, September 24th. They set an “outperform” rating and a $280.00 price objective on the stock. Bank of America lifted their target price on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. Oppenheimer cut ResMed from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 25th. Finally, Royal Bank of Canada lifted their target price on ResMed from $206.00 to $224.00 and gave the stock a “sector perform” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $218.18.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.